The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus after the company posted a 15% rise in 2025 DAYBUE royalties to A$65 million and a profit after tax of A$30 million.
Image source: Getty Images
What did Neuren Pharmaceuticals report?
- 2025 royalty income from DAYBUE® was A$65 million, up 15% from 2024
- Net profit after tax came in at A$30 million
- Cash and short-term investments stood at A$296 million at year end
- Completed A$50 million share buy-back; new buy-back program starts March 2026
- DAYBUE net sales reached US$391 million, up 12% year on year
- Cumulative DAYBUE income since launch now A$510 million
What else do investors need to know?
Neuren's partnership with Acadia Pharmaceuticals continues to deliver, with DAYBUE gaining approval for the new powder formulation (DAYBUE STIX) and a growing patient base in the US. Acadia's guidance for 2026 points to net sales of US$460–490 million, with potential Neuren royalties of A$70–77 million.
Development is progressing on Neuren's second drug, NNZ-2591, with the Koala Phase 3 trial in Phelan-McDermid syndrome now underway and FDA Fast Track designation secured. Neuren has also expanded its clinical pipeline and added the rare SYNGAP1-related disorder to its targets.
What did Neuren Pharmaceuticals management say?
Neuren CEO Jon Pilcher said:
In 2025 we achieved a critical milestone for Neuren's value creation strategy with the commencement of our Koala Phase 3 clinical trial of NNZ-2591 in Phelan-McDermid syndrome. There is so much to look forward to this year as we continue to execute that program towards a New Drug Application and in parallel advance NNZ-2591 for Pitt Hopkins syndrome and HIE. All of this is self-funded by our growing revenue from DAYBUE, which has now reached A$510 million since launch in 2023. We are very excited to watch the impact of the recent launch of DAYBUE STIX in the US as a potentially attractive new option for Rett syndrome patients and their families.
What's next for Neuren Pharmaceuticals?
Looking ahead, Neuren expects ongoing revenue growth from DAYBUE, especially with the broader US rollout of DAYBUE STIX and new regional market opportunities. The company remains well-funded to back its clinical programs, including the pivotal Phase 3 trial for NNZ-2591 and further indications.
A new share buy-back will launch in March 2026, with management highlighting confidence in Neuren's outlook and financial strength. Investors can watch for updates on European regulatory decisions, Japanese trial results, and further pipeline progress throughout the year.
Neuren Pharmaceuticals share price snapshot
Over the past 12 months, Neuren shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 11% over the same period.
